The Pharmacological Treatment of Alzheimer's Disease with Cholinesterase Inhibitors and Memantine

  • Gordon Keith Wilcock

The treatment of Alzheimer’s disease (AD) is now a fast evolving field of both basic scientific and clinical research. The use of the currently licensed cholinesterase inhibitor (ChEI) drugs is based on the findings in the midto- late 1970s, and early 1980s, of reduced levels of cholinergic markers in the brain of people who died with AD, mainly in the later stages of severe dementia. These changes were shown to correlate with the severity of pathological and clinical signs of the disease, and led to early attempts to evaluate physostigmine in AD patients (Davis, Mohs, & Tinklenberg, 1979), with more sophisticated trials following later (Asthana et al., 1995; Thal, Ferguson, Mintzer, Raskin, & Targum, 1999).


Mild Cognitive Impairment Alzheimer Disease Dementia With Lewy Body Vascular Dementia Neuropsychiatric Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amar, K., & Wilcock, G. K. (1996). Vascular dementia. British Medical Journals, 312, 227–231.Google Scholar
  2. Asthana, S., Raffaele, K. C., Berardi, A., Greig, N. H., Haxby, J. V., Schapiro, M. B., et al. (1995). Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. Alzheimer Disease and Associated Disorders, 9, 223–232.PubMedGoogle Scholar
  3. Black, S., Roman, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., et al. (2003). Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke, 34, 2323–2330.CrossRefPubMedGoogle Scholar
  4. Courtney, C., Farrell, D., Gray, R., Hills, R., Lynch, L., Sellwood, E., et al. (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet, 363, 2105–2115.CrossRefPubMedGoogle Scholar
  5. Craig, D., & Birks, J. (2005). Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews, CD004744.Google Scholar
  6. Cummings, J. L., & Masterman, D. L. (1998). Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. The Journal of Clinical Psychiatry, 59(Suppl. 13), 23–30.PubMedGoogle Scholar
  7. Davis, K. L., Mohs, R. C., & Tinklenberg, J. R. (1979). Enhancement of memory by physostigmine. The New England Journal of Medicine, 301, 946.PubMedGoogle Scholar
  8. Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. The New England Journal of Medicine, 351, 2509–2518.CrossRefPubMedGoogle Scholar
  9. Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002). Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet, 359, 1283–1290.CrossRefPubMedGoogle Scholar
  10. Farlow, M., Anand, R., Messina, J., Jr., Hartman, R., & Veach, J. (2000). A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. European Neurology, 44, 236–241.CrossRefPubMedGoogle Scholar
  11. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.CrossRefPubMedGoogle Scholar
  12. Francis, P. T., Nordberg, A., & Arnold, S. E. (2005). A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease? Trends in Pharmacological Sciences, 26, 104–111.CrossRefPubMedGoogle Scholar
  13. Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: A review of progress. Journal of Neurology, Neurosurgery, and Psychiatry, 66(2), 137–147.CrossRefPubMedGoogle Scholar
  14. Gauthier, S., Wirth, Y., & Mobius, H. J. (2005). Effects of memantine on behavioural symptoms in Alzheimer's disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry, 20, 459–464.CrossRefPubMedGoogle Scholar
  15. Guy, W. (1976). CGI: Clinical global impressions. In W. Guy (Ed.), ECDEU assessment manual for psychopharmacology (rev. ed., pp. 217–220). Rockville: National Institutes of Health.Google Scholar
  16. Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005). Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? The American Journal of Psychiatry,162, 676–682.CrossRefPubMedGoogle Scholar
  17. Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H. P., & van den Bussche H. (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. British Medical Journals,331, 321–327.CrossRefGoogle Scholar
  18. Kumar, V., Anand, R., Messina, J., Hartman, R., & Veach, J. (2000). An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology,7, 159–169.CrossRefPubMedGoogle Scholar
  19. Levy, M. L., Cummings, J. L., & Kahn-Rose, R. (1999). Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology, 45 (Suppl. 1), 15–22.CrossRefPubMedGoogle Scholar
  20. McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., et al. (2000). Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet,356, 2031–2036.CrossRefPubMedGoogle Scholar
  21. McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology,65, 1863–1872.CrossRefPubMedGoogle Scholar
  22. McShane, R., Areosa, S. A., & Minakaran, N. (2006). Memantine for dementia. Cochrane Database of Systematic Reviews, CD003154.Google Scholar
  23. Menendez-Gonzalez, M., Calatayud, M. T., & Blazquez-Menes, B. (2005). Exacerbation of Lewy bodies dementia due to memantine. Journal of Alzheimer's Disease,8, 289–291.PubMedGoogle Scholar
  24. Mohs, R. C., & Cohen, L. (1988). Alzheimer's disease assessment scale (ADAS). Psychopharmacology Bulletin,24, 627–650.PubMedGoogle Scholar
  25. Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science,258, 304–307.CrossRefPubMedGoogle Scholar
  26. Orgogozo, J. M., Rigaud, A. S., Stoffler, A., Mobius, H. J., & Forette, F. (2002). Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke,33, 1834–1839.CrossRefPubMedGoogle Scholar
  27. Panisset, M., Roudier, M., Saxton, J., & Boller, F. (1994). Severe impairment battery. A neuropsychological test for severely demented patients. Archives of Neurology,51, 41–45.PubMedGoogle Scholar
  28. Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine,352, 2379–2388.CrossRefPubMedGoogle Scholar
  29. Qizilbash, N., Birks, J., Lopez-Arrieta, J., Lewington, S., & Szeto, S. (2000). Tacrine for Alzheimer's disease. [Review] [5 refs]. Cochrane Database of Systematic Reviews, CD000202.Google Scholar
  30. Raskind, M. A., Peskind, E. R., Wessel, T., & Yuan, W. (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology,54, 2261–2268.PubMedGoogle Scholar
  31. Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer's disease. The New England Journal of Medicine,348, 1333–1341.CrossRefPubMedGoogle Scholar
  32. Reisberg, B., Schneider, L., Doody, R., Anand, R., Feldman, H., Haraguchi, H., et al. (1997). Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders, 11 (Suppl. 3), 8–18.PubMedGoogle Scholar
  33. Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. European Neuropsychopharmacology,10, 195–203.CrossRefPubMedGoogle Scholar
  34. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology,50, 136–145.PubMedGoogle Scholar
  35. Rogers, S. L., & Friedhoff, L. T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia,7, 293–303.PubMedGoogle Scholar
  36. Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal Bianco, P., et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. British Medical Journals, 318 (7184), 633–638.Google Scholar
  37. Schmitt, F. A., Ashford, W., Ernesto, C., Saxton, J., Schneider, L. S., Clark, C. M., et al. (1997). The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11 (Suppl. 2), S51–S56.PubMedGoogle Scholar
  38. Sclan, S. G., & Reisberg, B. (1992). Functional assessment staging (FAST) in Alzheimer's disease: Reliability, validity, and ordinality. International Psychogeriatrics, 4 (Suppl. 1), 55–69.CrossRefPubMedGoogle Scholar
  39. Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K., & Kling, A. (1986). Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. The New England Journal of Medicine,315, 1241–1245.PubMedCrossRefGoogle Scholar
  40. Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., & Gergel, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. The Journal of American Medical Association,291, 317–324.CrossRefGoogle Scholar
  41. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., & Ding, C. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology,54, 2269–2276.PubMedGoogle Scholar
  42. Thal, L. J., Ferguson, J. M., Mintzer, J., Raskin, A., & Targum, S. D. (1999). A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology,52, 1146–1152.PubMedGoogle Scholar
  43. Trinh, N. H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003). Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. The Journal of American Medical Association,289, 210–216.CrossRefGoogle Scholar
  44. Venneri, A., McGeown, W. J., & Shanks, M. F. (2005). Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport,16, 107–110.CrossRefPubMedGoogle Scholar
  45. Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I., & Lewis, K. W. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. The Journal of American Medical Association,271, 992–998.CrossRefGoogle Scholar
  46. Wilcock, G., Howe, I., Coles, H., Lilienfeld, S., Truyen, L., Zhu, Y., et al. (2003). A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging,20, 777–789.CrossRefPubMedGoogle Scholar
  47. Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. Galantamine International-1 Study Group. British Medical Journals,321, 1445–1449.CrossRefGoogle Scholar
  48. Wilcock, G., Mobius, H. J., Stoeffler, A., & on behalf of the MMM 500 group (2002). A double-blind placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). International Clinical Psychopharmacology,17, 297–305.CrossRefPubMedGoogle Scholar
  49. Wilcock, G., Stoeffler, A., Sahin, K., & Mobius, H. J. (2000). Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. European Neuropsychopharmacology, 10 (Suppl. 3), S360.CrossRefGoogle Scholar
  50. Wilkinson, D. G., Passmore, A. P., Bullock, R., Hopker, S. W., Smith, R., Potocnik, F. C., et al. (2002). A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. International Journal of Clinical Practice,56, 441–446.PubMedGoogle Scholar
  51. Wimo, A., Wetterholm, A. L., Mastey, V., & Winblad, B. (1998). Evaluation of the healthcare resource utilisation and caregiver time in anti-dementia drug trials. In A. Wimo, B. Jonsson, G. Karlsson, & B. Winblad (Eds.), Health economics of dementia (pp. 465–499). Chichester: John Wiley.Google Scholar
  52. Winblad, B., Kilander, L., Eriksson, S., Minthon, L., Batsman, S., Wetterholm, A. L., et al. (2006). Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet,367, 1057–1065.CrossRefPubMedGoogle Scholar
  53. Winblad, B., & Poritis, N. (1999). Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). International Journal of Geriatric Psychiatry,14, 135–146.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Gordon Keith Wilcock
    • 1
  1. 1.Nuffield Department of MedicineUniversity of OxfordUK

Personalised recommendations